title: Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer.
abstract: Reactivation of hepatitis B virus (HBV) has recently been reported as a fatal complication in patients undergoing cytotoxic chemotherapy. We herein describe a case of reactivation in a 76-year-old man who had undergone pelvic exenteration for colorectal cancer (CRC). He was treated with a modified FOLFOX6 chemotherapy regimen after the operation. Thirteen months later, his laboratory data showed severe liver dysfunction. His hepatitis B surface antigen (HBsAg) test was positive, and his HBV-DNA level was elevated. We diagnosed the patient with HBV reactivation as his HBsAg test was negative before starting chemotherapy. His liver dysfunction improved after administration of entecavir. This is the first report describing HBV reactivation following chemotherapy for an HBsAg-negative CRC patient.
authors.affiliation: Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Okagawa
authors.forename: Kohichi
authors.initials: K
authors.lastname: Takada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hisai
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Koshiba
authors.forename: Hironori
authors.initials: H
authors.lastname: Wada
authors.forename: Etsu
authors.initials: E
authors.lastname: Miyazaki
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kanari
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kawano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iyama
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sato
authors.forename: Koji
authors.initials: K
authors.lastname: Miyanishi
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobune
authors.forename: Rishu
authors.initials: R
authors.lastname: Takimoto
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005472:Fluorouracil / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006509:Hepatitis B / Q000139:chemically induced* / Q000188:drug therapy* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D009944:Organoplatinum Compounds / Q000009:adverse effects; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D009944:Organoplatinum Compounds; C413685:entecavir; D006147:Guanine; D002955:Leucovorin; D005472:Fluorouracil